ArticleChemical science2026
Supramolecular protecting groups can impart prosthetic stereoselectivity to catalytic systems employing unmodified achiral heterogenous catalysts.
Article in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Use of homogeneous catalysis - typically based on scarce precious metals - remains a dominant approach to afford good yields of enantiopure compounds. Combining typical strengths of heterogenous catalysts (low cost, sustainable, recyclable) with those of precious metal-mediated homogenous catalysis (amenability to design for selectivity) is desirable: several approaches have been demonstrated (chiral material surfaces, modification of surfaces with chiral auxiliaries, immobilisation of chiral catalysts), but it remains a challenge. Here we present a systems catalysis approach, with a heterogeneous material providing catalytic activity, and a separate host species controlling access to the catalyst to impart 'prosthetic' chiral selectivity. Since this non-covalent analogue to conventional covalent protecting group strategies is modular, the same substrate/host combination may be applied to a range of catalytic surfaces. The potential of this approach to achieve effective kinetic resolution is demonstrated in stereoselective synthesis of the drug (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.